• Hematoxylin and Eosin Staining Kit Guide

  2026-08-16

  The Hematoxylin and Eosin Staining Kit provides ready-to-use hematoxylin and eosin solutions for visualizing cellular and tissue morphology in research samples. It is suitable for paraffin-embedded and frozen sections and cytological preparations, but it is not intended for diagnostic, medical, or clinical decision-making.

• Nilotinib Restores MHC-I in Colorectal Cancer

  2026-08-15

  Dong et al. show that Nilotinib, also known as AMN-107, can restore MHC-I expression in colorectal cancer cells and improve CD8+ T-cell-mediated killing. The study identifies a dual mechanism involving cGAS-STING-NF-κB-dependent MHC-I transcription and reduced PCSK9-associated MHC-I degradation, providing a preclinical rationale for combining Nilotinib with anti-PD-L1 therapy.

• Dasatinib Monohydrate: From Kinase Control to CML Insight

  2026-08-14

  Dasatinib Monohydrate (BMS-354825) is more than a potent ABL-directed compound: it is a translational probe for separating oncogenic kinase suppression from treatment-associated immune and vascular biology. This article connects imatinib-resistant BCR-ABL inhibition with emerging evidence on neutrophil extracellular traps in chronic myeloid leukemia research and outlines a disciplined strategy for validating mechanism, resistance, and translational relevance.

• Hydrazide VEGFR-2 Inhibitors: SA7 and Antiangiogenesis

  2026-08-14

  Fatale and colleagues report 53 hydrazide-based derivatives designed to inhibit VEGFR-2 and suppress angiogenesis. SA7 showed kinase inhibition comparable to sorafenib, inhibited endothelial tube formation, and reduced HCT116 xenograft growth, making it a useful lead for investigating antiangiogenic and antiproliferative mechanisms.

• Anlotinib hydrochloride Angiogenesis Assays

  2026-08-13

  Anlotinib hydrochloride enables mechanism-focused angiogenesis experiments spanning endothelial migration, tube formation, receptor phosphorylation, and ERK pathway activity. This practical guide explains how to build reproducible workflows, compare anti-angiogenic agents, and troubleshoot common assay failures in cancer research.

• Nintedanib (BIBF 1120): A Translational Test

  2026-08-13

  Nintedanib (BIBF 1120) offers a strategically useful way to interrogate VEGFR, FGFR, and PDGFR signaling across oncology and fibrosis models. This article connects its triple angiokinase mechanism with ATRX-defined glioma vulnerability, experimental design, biomarker strategy, and translational decision-making.

• Fenipentol: Applied Workflows and Troubleshooting

  2026-08-13

  Fenipentol, also called 1-Phenyl-1-pentanol, supports exploratory studies spanning hepatobiliary secretion, estrogen receptor biology, and assay-guided liver research. This practical guide emphasizes reproducible stock preparation, secretion workflows, isomer-aware interpretation, and troubleshooting rather than treating docking or historical pharmacology as clinical proof.

• GLI2, WNT, and Prostaglandins in Immune Evasion

  2026-08-12

  DeVito et al. identify GLI2 as a mechanistic hub linking mesenchymal transformation to tumor immune evasion and resistance to anti-PD-1 therapy. The study shows that GLI2 coordinates WNT ligand production and prostaglandin signaling, reshaping myeloid and lymphoid immune compartments and providing a rationale for pathway-directed combination studies.

• Thiothixene: From PK Evidence to Efferocytosis

  2026-08-11

  Thiothixene is a typical antipsychotic agent with an unusually informative research profile spanning dopamine receptor pharmacology, macrophage efferocytosis, and drug-interaction analysis. This article explains how pharmacokinetic evidence can sharpen interpretation of Thiothixene-based neuroimmune assays without conflating clinical exposure with in vitro activity.

• SCUBE3 Antibody Therapy Rewires Cancer Signaling

  2026-08-11

  The reference study identifies secreted SCUBE3 as a multifunctional cancer dependency that links oncogenic receptor signaling, DNA damage repair, therapy resistance, and immune suppression. Its neutralizing antibody approach produced antitumor activity in preclinical models by disrupting SCUBE3-associated FOXR2 and c-Myc signaling while restoring immune-related gene expression.

• Rimonabant (SR141716) in Mechanistic Pain Assays

  2026-08-10

  Rimonabant (SR141716) gives researchers a selective CB1 blockade tool for separating cannabinoid-dependent behavior from adenosine A2A-mediated effects in terpene and neuropathic-pain studies. Its high CB1 selectivity also supports appetite regulation research, obesity research, inflammatory assays, and controlled endocannabinoid-system experiments.

• Phenacetin in Human Intestinal Organoid PK

  2026-08-09

  Phenacetin can serve as a chemically defined benchmark for translational pharmacokinetic studies when evaluated in human pluripotent stem cell-derived intestinal organoids. This article connects the compound’s absorption and metabolism questions with recent organoid advances, while emphasizing vehicle control, analytical endpoints, nephropathy-related safety boundaries, and research-only use.

• Doxorubicin: From DNA Damage to Cardiotoxicity

  2026-08-08

  Doxorubicin, also known as Adriamycin, is a powerful DNA-directed cancer chemotherapy drug and a valuable mechanistic probe. This article connects its tumor-cell activity with cardiotoxicity research and shows how assay design, timing, and orthogonal readouts improve interpretation.

• 6-Thioguanine Chitosan Nanoparticles in Cancer Models

  2026-08-07

  This study investigated chitosan nanoparticles as a delivery system for 6-thioguanine, with or without curcumin, to address the drug’s limited bioavailability and short half-life. The formulation produced sustained release and stronger in vitro responses than free 6-thioguanine in selected breast and ovarian cancer models, while also providing evidence of apoptosis, G2/M arrest, and DNA demethylating activity.

• Precision Caspase-3/7 Inhibition: Translational Impact for A

  2026-08-07

  Explore the mechanistic depth and translational strategies enabled by selective, reversible caspase-3/7 inhibition. This article integrates recent host-pathogen research, advanced workflow insights, and practical guidance for leveraging Caspase-3/7 Inhibitor I in apoptosis modulation—from mechanistic cell death dissection to disease model innovation.

16783 records 1/1119 page Next 12345 下5页 Last page